ArticleOncotarget2018
Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.Annals of surgical oncology · 2021Trial
- Article
- Somatic gene variation profiles in geriatric and adult malignant melanoma patients.Frontiers in oncology · 2025Article
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- ASO Author Reflections: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.Annals of surgical oncology · 2024Article
- Article
- Topographical and Chronological Analysis of Thin Cutaneous Melanoma's Progressions: A Multicentric Study.Cancers · 2023Article
- The Importance of Immunohistochemistry in the Evaluation of Tumor Depth of Primary Cutaneous Melanoma.Diagnostics (Basel, Switzerland) · 2023Article
- The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms.Cancers · 2022Article
- Dermoscopy for Cutaneous Melanoma: Under the Eye of Both the Dermatologist and the Legal Doctor.Dermatology practical & conceptual · 2022Review
- Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies.Frontiers in oncology · 2021Review
- Clinicopathologic Features of Cutaneous Malignant Melanoma and Their Impact on Prognosis.Cureus · 2020Article
- Tumoral inflammatory infiltrate does not predict metastases in thin primary cutaneous melanomas.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases. Existing prognostic factors cannot reliably differentiate TM patients at risk for metastases.
objectiveWe aimed at characterizing the clinical-pathologic and mutation profile of metastatic and not-metastatic TM in order to distinguish lesions at risk of metastases.
methodsClinical-pathologic characteristics were recorded for the TM cases analyzed. We used a Next Generation Sequencing (NGS) multi-gene panel to characterize TM for multiple somatic mutations.
resultsA statistically significant association emerged between the presence of metastases and Breslow thickness ≥0.6 mm (
conclusionOur study indicates Breslow thickness ≥0.6 mm as a valid prognostic factor to distinguish TM at risk for metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.